AIAxios1h ago
OpenAI acquires Orchestra Bio, which builds AI agents for managing drug
OpenAI acquires Orchestra Bio, which builds AI agents for managing drug development, and plans to integrate its tech into OpenAI life sciences suite Rosalind
TL;DROpenAI bought Orchestra Bio to add drug development AI agents to its Rosalind life sciences platform.
Why it matters: OpenAI expands beyond chatbots into biotech, potentially accelerating drug discovery timelines and influencing pharma AI adoption.
OpenAI has acquired Orchestra Bio, a startup building AI agents to help pharmaceutical companies manage drug development, the ChatGPT maker shared exclusively with Axios.
Read full articleSource: Axios · Opens in new tab